The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as ibrutinib …

Patients with chronic lymphocytic leukemia can be divided into three categories: those who
are minimally affected by the problem, often never requiring therapy; those that initially …

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with
ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were …

Chronic lymphocytic lymphoma (CLL) has one of the highest familial risks among cancers.
Monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, has a higher prevalence …

The term monoclonal B-cell lymphocytosis (MBL) describes the presence of a clonal B cell
population with a count of less than 5× 109/L and no symptoms or signs of disease. Based …

Next‐generation sequencing identified about 60 genes recurrently mutated in chronic
lymphocytic leukemia (CLL). We examined the additive prognostic value of the total number …

Monoclonal B-cell lymphocytosis (MBL) progresses to chronic lymphocytic leukemia (CLL)
requiring therapy at 1% to 5% per year. Improved prediction of progression would greatly …

Chronic lymphocytic leukemia (CLL) is a neoplasm of B-cells in the blood and monoclonal B-
cell lymphocytosis (MBL) is a precursor state to CLL. This narrative review provides an …

Objective To examine mortality and morbidity patterns before and after premalignancy
diagnosis in individuals with monoclonal gammopathy of undetermined significance …